Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies
News May 21, 2013
The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's trending in the field of nucleic acids. Blog posts include interviews with industry thought leaders, discussions of research presented at conferences and meetings, reviews of current publications and more.
Dr. Zon (PhD Princeton University 1971) developed automated synthesis of DNA analogs at the National Institutes of Health, and later at Applied Biosystems (ABI). In 1992 he co-founded ABI spin-off Lynx Therapeutics, an antisense company. He returned to ABI in 1999 to head DNA sequencing R&D, and then worked on novel methods for DNA sequencing as a Research Fellow at Life Technologies. In 2006, Dr. Zon was admitted as a Fellow of The Royal Society of Chemistry in the UK. At TriLink BioTechnologies since 2011, he is now Director of Business Development. Dr. Zon has published over 260 papers and patents, and is a longtime member of the Editorial Board for Analytical Biochemistry.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.